ethyl 4-hydroxy-2,6-dimethylpyridin-3-carboxylate | 33831-56-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: ethyl 4-hydroxy-2,6-dimethylpyridin-3-carboxylate
• 英文别名: 2,6-dimethyl-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid ethyl ester；4-hydroxy-2,6-dimethyl-nicotinic acid ethyl ester；4-Hydroxy-2,6-dimethyl-nicotinsaeure-aethylester；ethyl 4-hydroxy-2,6-dimethylpyridine-3-carboxylate
• CAS: 33831-56-0
• 化学式: C₁₀H₁₃NO₃
• mdl: MFCD03034540
• 分子量: 195.218
• InChiKey: DLHHQCQHFXZHRR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 4-hydroxy-2,6-dimethylpyridin-3-carboxylate 在 alkaline solution 作用下， 生成 2,6-dimethyl-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid
  参考文献：
  名称：

  Collie, Justus Liebigs Annalen der Chemie, 1884, vol. 226, p. 310,312

  摘要：

  DOI：
• 作为产物：
  描述：

  3-氨基巴豆酸乙酯 生成 ethyl 4-hydroxy-2,6-dimethylpyridin-3-carboxylate
  参考文献：
  名称：

  Collie, Journal of the Chemical Society, 1895, vol. 67, p. 222

  摘要：

  DOI：

文献信息

• Novel Angiotensin II Receptor Antagonists. Design, Synthesis, and in Vitro Evaluation of Dibenzo[a,d]cycloheptene and Dibenzo[b,f]oxepin Derivatives. Searching for Bioisosteres of Biphenyltetrazole Using a Three-Dimensional Search Technique
  作者：Ryuichi Kiyama、Tsunetoshi Honma、Kunio Hayashi、Masayoshi Ogawa、Mariko Hara、Masafumi Fujimoto、Toshio Fujishita

  DOI：10.1021/jm00014a024

  日期：1995.7

  Three-dimensional substructure searching (3D search), using the program MACCS-3D, was utilized for designing novel angiotensin II receptor antagonists which contain a bioisostere of the biphenylyltetrazole moiety of DuP 753. A 3D query was prepared from an overlay model of substructures of several potent AII antagonists. The search system retrieved 139 compounds from the database MDDR-3D, which consisted

  使用程序MACCS-3D进行三维子结构搜索（3D搜索），用于设计新型血管紧张素II受体拮抗剂，该拮抗剂包含DuP 753的联苯甲酰四唑部分的生物等排体。从3D子结构的覆盖模型制备3D查询几种有效的AII拮抗剂。该搜索系统从数据库MDDR-3D中检索了139种化合物，其中包括29,400种药用专利化合物。从检索到的化合物中选择三环化合物，然后考虑对覆盖模型的空间适应性和合成可行性进行进化。最后，设计并合成了具有二苯并[a，d]环庚烯或二苯并[b，f] oxepin的各种新型AII拮抗剂。该系列几个成员的受体结合活性（Ki）在10（-10）M范围内，
• Heterocyclic analogs of benzamide antiarrhythmic agents
  作者：Reda Hanna、John W. Lampe、William C. Lumma、Paul W. Erhardt、Samuel S. Wong、Mark E. Sullivan

  DOI：10.1021/jm00123a033

  日期：1989.3

  A series of heterocyclic N-[(diethylamino)alkyl]arenamides related to acecainide was prepared and examined for antiarrhythmic activity. The compounds were synthesized from the corresponding known heterocyclic carboxylic acids or esters by using standard amide formation methods. The effects of the compounds on the electrophysiological properties of canine Purkinje fibers and ventricular muscle strips

  制备了一系列与乙酰醋胺有关的杂环N-[（（二乙基氨基）烷基]芳酰胺，并检查了其抗心律失常活性。通过使用标准酰胺形成方法，由相应的已知杂环羧酸或酯合成化合物。确定了这些化合物对犬浦肯野纤维和心室肌条的电生理特性的影响。大多数化合物显示出与弱I类活性一致的作用。显示了两种化合物，N- [2-（二乙基氨基）乙基] -3,4,5-三甲基-1H-吡咯-2-羧酰胺和N- [2-（二乙基氨基）乙基] -1H-吲哚-2-羧酰胺延长动作电位持续时间和功能不应期，表明适度的III类电生理活性。通过使用分子建模技术检查了代表性化合物。活性类别不同的​​化合物在质量上显示出不同的静电势图。
• Angiotensin II antagonizers which are condensed pyridine derivatives
  申请人：Imperial Chemical Industries PLC

  公开号：US05130318A1

  公开（公告）日：1992-07-14

  The invention concerns pharmaceutically useful novel compounds of the formula I, in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, X and Z have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositions containing them. The novel compounds are of value in treating conditions such as hypertension and congestive heart failure. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.

  这项发明涉及具有以下结构的药用新化合物（公式I），其中R.sup.1、R.sup.2、R.sup.3、R.sup.4、R.sup.5、R.sup.6、R.sup.7、X和Z具有此处定义的各种含义，以及它们的无毒盐和含有它们的药物组合物。这些新化合物对于治疗高血压和充血性心力衰竭等疾病具有价值。该发明还涉及制造这些新化合物的过程以及将这些化合物用于医疗治疗的用途。
• Nitrogenous heterocyclic derivative, medicinal composition containing the same, medical use thereof, and intermediate therefor
  申请人：Nishimura Toshihiro

  公开号：US20050049203A1

  公开（公告）日：2005-03-03

  The present invention provides nitrogen-containing heterocyclic derivatives represented by the general formula: wherein X 1 and X 3 independently represent N or CH; X 2 represents N or CR 2 ; X 4 represents N or CR 3 ; and with the proviso that one or two of X 1 , X 2 , X 3 and X 4 represent N; R 1 represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted(lower alkoxy) group, a lower alkoxy(lower alkoxy) -substituted (lower alkyl) group, a cyclic lower alkyl group, a halo(lower alkyl) group or a group represented by the general formula: HO-A—wherein A represents a lower alkylene group, a lower alkyleneoxy group or a lower alkylenethio group; R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, a cyclic lower alkyl group, a lower alkoxy group, an amino group, a (lower acyl)amino group, a mono(lower alkyl)amino group or a di(lower alkyl)amino group; and R 3 represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, or prodrugs thereof which are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutical compositions comprising the same, and pharmaceutical uses and production intermediates thereof.

  本发明提供了一种以通式表示的含氮杂环衍生物： 其中，X1和X3独立地表示N或CH；X2表示N或CR2；X4表示N或CR3；并且假定X1、X2、X3和X4中的一个或两个表示N；R1表示氢原子、卤素原子、低碳基、低烷氧基、低硫代烷基、低烷氧基取代的（低烷基）基团、低烷氧基取代的（低烷氧基）基团、低烷氧基（低烷氧基）取代的（低烷基）基团、环状低烷基、卤素（低烷基）基团或由通式HO-A-表示的基团，其中A表示低碳亚烷基、低碳亚烷氧基或低碳亚烷硫基；R2表示氢原子、卤素原子、低碳基、环状低碳基、低烷氧基、氨基、（低酰基）氨基、单（低烷基）氨基或双（低烷基）氨基；R3表示氢原子或低碳基，或其药学上可接受的盐，或其前药，其作为预防或治疗与高血糖相关的疾病，如糖尿病、糖尿病并发症或肥胖症的药剂，包括这些药剂的制剂和制备中间体。
• Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors
  申请人：Gupta Ramesh Chandra

  公开号：US20100010035A1

  公开（公告）日：2010-01-14

  The present invention relates to new compounds of the formula [Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, R3, and R31 are as specified herein. The invention also relates to a method for preparation thereof, as well as combinations of the new compounds with previously known agents. The invention also relates to the use of the above-mentioned compounds and combinations for the preparation of a medicament for treating hypertension of different kinds, alleviating organ damage of different kinds, treating or preventing diabetic nephropathy, treating endothelin and angiotensin mediated disorders, and treating prostate cancer.

  本发明涉及一种新的化合物，其化学式为[应在此处插入化学式。请参见纸质副本]，其中R1、R2、R3和R31如本文所述。本发明还涉及一种制备该化合物的方法，以及新化合物与先前已知药剂的组合。本发明还涉及上述化合物和组合物的用途，用于制备治疗不同类型的高血压、缓解不同类型的器官损伤、治疗或预防糖尿病肾病、治疗内皮素和血管紧张素介导的疾病以及治疗前列腺癌的药物。